<DOC>
	<DOCNO>NCT01405872</DOCNO>
	<brief_summary>The primary objective study determine physician report persistence Avonex PEN Month 12/End Study well determine factor associate persistence . The secondary objective study follow : To evaluate tolerability treatment administration Avonex PEN Months 3 , 6 , 12 ; To evaluate patient quality life ( QoL ) use Avonex PEN treatment administration Months 3 , 6 , 12 ; To evaluate clarity direction use Avonex PEN Month 3 ; To evaluate ease use patient 's assessment injection procedure Avonex PEN Months 3 , 6 , 12 ; To evaluate patient report adherence Months 6 12 ; To evaluate physician report persistence Month 6 ; To evaluate overall patient satisfaction use Avonex PEN treatment administration Months 3 , 6 , 12 ; To evaluate patient report fear injection Months 3 , 6 , 12 ; To evaluate percentage patient switch caregiver self-injection Months 3 , 6 , 12 .</brief_summary>
	<brief_title>Persistence , Adherence , Quality Life , Treatment Satisfaction With Avonex® PEN™ .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Ability understand purpose risk study provide sign date informed consent Must satisfy locally approve therapeutic indication Avonex PEN Decision treat Avonex PEN must precede enrollment Must two ( 2 ) injection Avonex PEN prior enrollment Inability comply study requirement Other unspecified reason , opinion investigator Biogen Idec , make patient unsuitable enrollment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>